Long-Term Data Supports Sanofi's AYVAKIT
Blueprint Medicines, a Sanofi company, announced four-year data from its PIONEER study on the drug AYVAKIT. The results show a sustained benefit and long-term safety profile for patients with indolent systemic mastocytosis, a rare blood disorder.
AYVAKIT (avapritinib) is a precision therapy designed to target the primary driver of the disease in about 95% of cases, a genetic mutation known as KIT D816V. This mutation causes an overproduction of mast cells, leading to the disorder's symptoms. Indolent systemic mastocytosis, the most common form of systemic mastocytosis, causes a wide range of debilitating symptoms. Patients can experience everything from skin lesions and severe itching to gastrointestinal issues, bone pain, fatigue, and "brain fog." The PIONEER trial measured the drug's effectiveness using a Total Symptom Score (TSS). Results at 24 weeks showed a statistically significant improvement in symptoms for patients taking AYVAKIT compared to placebo, with these benefits deepening over time. Key secondary goals, like reducing mast cell burden in bone marrow and lowering serum tryptase levels, were also met. The U.S. Food and Drug Administration (FDA) first approved AYVAKIT in January 2020 for a type of gastrointestinal stromal tumor (GIST) with a specific mutation. Its approval was later expanded to include advanced systemic mastocytosis in June 2021 and indolent systemic mastocytosis in May 2023. This long-term data comes after Sanofi completed its acquisition of Blueprint Medicines in July 2025 for approximately $9.1 billion. The acquisition was a strategic move to bolster Sanofi's rare disease and immunology portfolio, with AYVAKIT being a key asset.
